Whan In Pharm Co.,Ltd.

KSE 016580.KS

Whan In Pharm Co.,Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 275.10 M

Whan In Pharm Co.,Ltd. Shareholders' Equity is USD 275.10 M for the year ending December 31, 2023, a 4.41% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Whan In Pharm Co.,Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 263.47 M, a -0.68% change year over year.
Whan In Pharm Co.,Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 265.28 M, a -2.41% change year over year.
Whan In Pharm Co.,Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 271.83 M, a 15.19% change year over year.
Whan In Pharm Co.,Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 236.00 M, a 1.69% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 016580.KS

Whan In Pharm Co.,Ltd.

CEO	Mr. Wonbum Lee
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Whanin Building, 11
Employees	582
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Whan In Pharm Co.,Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. It offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years